{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:33:35Z","timestamp":1791027215346,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijcard.2012.12.018","type":"journal-article","created":{"date-parts":[[2013,1,6]],"date-time":"2013-01-06T09:16:18Z","timestamp":1357463778000},"page":"1772-1782","source":"Crossref","is-referenced-by-count":72,"title":["Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges"],"prefix":"10.1016","volume":"167","author":[{"given":"Faiez","family":"Zannad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Gattis","family":"Stough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W.A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2012.12.018_bb0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-8703(81)90739-0","article-title":"Neurohumoral control mechanisms in congestive heart failure","volume":"102","author":"Cohn","year":"1981","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"issue":"Suppl. 7A","key":"10.1016\/j.ijcard.2012.12.018_bb0020","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/S0002-9343(98)00385-4","article-title":"Pathophysiology of chronic heart failure","volume":"110","author":"Francis","year":"2001","journal-title":"Am J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2012.12.018_bb0025","first-page":"S14","article-title":"Pathophysiology of congestive heart failure","volume":"4","author":"Francis","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0035","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Cibis II Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0060","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0065","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0090","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11886-004-0019-6","article-title":"Is too much neurohormonal blockade harmful?","volume":"6","author":"Anand","year":"2004","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0100","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0735-1097(03)00245-6","article-title":"Heart failure therapy at a crossroad: are there limits to the neurohormonal model?","volume":"41","author":"Mehra","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/euhj.2001.2973","article-title":"Hospitalization of patients with heart failure: a population-based study","volume":"23","author":"Cowie","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0110","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","article-title":"Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0115","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0120","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ahj.2005.04.035","article-title":"Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)","volume":"150","author":"Teerlink","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0135","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.294.13.1625","article-title":"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial","volume":"294","author":"The ESCAPE Investigators and ESCAPE Study Coordinators","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0140","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0145","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.2011.1474","article-title":"National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998\u20132008","volume":"306","author":"Chen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0150","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0160","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cardfail.2005.07.007","article-title":"Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design","volume":"12","author":"Pullicino","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0170","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/CIRCHEARTFAILURE.110.959957","article-title":"Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions","volume":"4","author":"Bettari","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0180","first-page":"1424","article-title":"Does heart failure confer a hypercoagulable state? Virchow's triad revisited","volume":"33","author":"Lip","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.amjcard.2010.10.029","article-title":"The risk of thromboembolism in heart failure: does it merit anticoagulation therapy?","volume":"107","author":"Shantsila","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0190","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.CCM.0000297160.48694.90","article-title":"Cytokines and acute heart failure","volume":"36","author":"Chen","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0195","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0002-9149(99)00098-3","article-title":"Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure","volume":"83","author":"O'Connor","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0200","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/0735-1097(95)00049-A","article-title":"The coagulation system is activated in idiopathic cardiomyopathy","volume":"25","author":"Yamamoto","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.106.640698","article-title":"Hemodynamic modulation of endocardial thromboresistance","volume":"115","author":"Kapur","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0210","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.amjcard.2005.09.113","article-title":"Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes","volume":"97","author":"Chong","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0215","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0735-1097(96)00398-1","article-title":"Mechanisms underlying the morning increase in platelet aggregation: a flow cytometry study","volume":"28","author":"Andrews","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1152\/jappl.1999.86.1.133","article-title":"Norepinephrine, but not epinephrine, enhances platelet reactivity and coagulation after exercise in humans","volume":"86","author":"Ikarugi","year":"1999","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0300-9572(02)00213-7","article-title":"Effect of stress hormones on the expression of fibrinogen-binding receptors in platelets","volume":"55","author":"Lam","year":"2002","journal-title":"Resuscitation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0230","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0002-8703(82)90154-5","article-title":"In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction","volume":"104","author":"Sorkin","year":"1982","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0235","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/cc6931","article-title":"In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury","volume":"12","author":"Tschuor","year":"2008","journal-title":"Crit Care"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0240","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.63.3.552","article-title":"Platelets, thromboembolism and mitral valve prolapse","volume":"63","author":"Walsh","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0049-3848(96)00199-5","article-title":"Synergistic effect of epinephrine and shearing on platelet activation","volume":"84","author":"Goto","year":"1996","journal-title":"Thromb Res"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0250","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/eurheartj\/14.2.205","article-title":"Platelet function, thrombin and fibrinolytic activity in patients with heart failure","volume":"14","author":"Jafri","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0255","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0002-8703(94)90670-X","article-title":"Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure","volume":"127","author":"Sbarouni","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0260","first-page":"50","article-title":"Cytokines and heart failure","volume":"1","author":"Paulus","year":"2000","journal-title":"Heart Fail Monit"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0265","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0270","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/ATVBAHA.109.188656","article-title":"Activated protein C protects against myocardial ischemia\/reperfusion injury via inhibition of apoptosis and inflammation","volume":"29","author":"Loubele","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/CCM.0b013e318192fe4f","article-title":"Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress","volume":"37","author":"Sennoun","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0280","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCRESAHA.110.226456","article-title":"Microparticles: protagonists of a novel communication network for intercellular information exchange","volume":"107","author":"Mause","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0285","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.110.233056","article-title":"Microparticles in hemostasis and thrombosis","volume":"108","author":"Owens","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0290","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/eurjhf\/hfq145","article-title":"Prognostic value of endothelial microparticles in patients with heart failure","volume":"12","author":"Nozaki","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0295","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/eurheartj\/ehq478","article-title":"Circulating CD31+\/Annexin V+ microparticles correlate with cardiovascular outcomes","volume":"32","author":"Sinning","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0300","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0305","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0310","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0315","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM199006073222302","article-title":"Activation of coagulation after administration of tumor necrosis factor to normal subjects","volume":"322","author":"van der Poll","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0320","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00001721-200309000-00001","article-title":"Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis","volume":"14","author":"Chin","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0325","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1365-2362.2003.01252.x","article-title":"Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure","volume":"33","author":"Chin","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0330","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0335","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0340","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","article-title":"Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial","volume":"102","author":"Uretsky","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0345","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/01.CIR.0000084543.79097.34","article-title":"Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure","volume":"108","author":"Horwich","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0350","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ejheart.2007.05.007","article-title":"The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T","volume":"9","author":"Metra","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0355","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Peacock","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0360","first-page":"CR90","article-title":"High levels of troponin T are associated with ventricular remodeling and adverse in-hospital outcome in heart failure","volume":"10","author":"Perna","year":"2004","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0365","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijcard.2004.01.017","article-title":"Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure","volume":"99","author":"Perna","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0370","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCHEARTFAILURE.111.961581","article-title":"Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study","volume":"4","author":"O'Connor","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0375","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1161\/CIRCULATIONAHA.106.661397","article-title":"Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)","volume":"115","author":"Freudenberger","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0380","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001721-200306000-00004","article-title":"Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study","volume":"14","author":"Alikhan","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0385","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group","volume":"341","author":"Samama","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0390","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.amjcard.2006.03.064","article-title":"Risk of venous thromboembolism in patients hospitalized with heart failure","volume":"98","author":"Beemath","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0395","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0400","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"Leizorovicz","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0405","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCHEARTFAILURE.109.892349","article-title":"Venous thromboembolism in hospitalized patients with heart failure: incidence, prognosis, and prevention","volume":"3","author":"Ng","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0410","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjmed.2010.10.014","article-title":"Venous thromboembolism in heart failure: preventable deaths during and after hospitalization","volume":"124","author":"Piazza","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0415","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0420","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1378\/chest.128.4.2576","article-title":"Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit","volume":"128","author":"Darze","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0425","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.amjmed.2005.11.035","article-title":"Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure","volume":"119","author":"Monreal","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0430","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme\u2013 a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis","volume":"24","author":"Cleland","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0435","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1378\/chest.06-2077","article-title":"Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients","volume":"131","author":"Darze","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0440","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0735-1097(98)00359-3","article-title":"Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators","volume":"32","author":"Grubman","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0445","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study","volume":"8","author":"Cokkinos","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0450","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(97)00502-0","article-title":"Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0455","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJM199701233360403","article-title":"Ventricular dysfunction and the risk of stroke after myocardial infarction","volume":"336","author":"Loh","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0460","first-page":"VI94","article-title":"Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Dunkman","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0465","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0033-0620(98)80057-1","article-title":"Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure","volume":"41","author":"Garg","year":"1998","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0470","first-page":"CD003336","article-title":"Anticoagulation for heart failure in sinus rhythm","author":"Lip","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ijcard.2012.12.018_bb0475","first-page":"461","article-title":"Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm","volume":"95","author":"Lip","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0480","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurjhf\/hfs073","article-title":"Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis","volume":"14","author":"Lip","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0485","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0490","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0495","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0500","first-page":"232","article-title":"Impact of bivalirudin therapy on mortality in patients with high risk features undergoing PCI: a patient-level pooled analysis from the REPLACE-2, ACUITY, and HORIZONS-AMI trials [abstract]","volume":"32","author":"Dangas","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0505","unstructured":"Gibson CM. PREMIER [Abstract]. Eur Heart J 2012; to be updated after ESC 2012."},{"key":"10.1016\/j.ijcard.2012.12.018_bb0510","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jacc.2009.11.057","article-title":"Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study","volume":"55","author":"Bonde","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0515","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00002512-200825010-00009","article-title":"Fondaparinux: use in thromboprophylaxis of acute medical patients","volume":"25","author":"Dhillon","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0520","first-page":"50","article-title":"Fondaparinux reduces symptomatic pulmonary embolism and death in patients hospitalized with congestive heart failure: a sub-analysis of the randomized ARTEMIS trial [abstract P477]","volume":"28","author":"Eikelboom","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0525","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ahj.2010.10.005","article-title":"Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study","volume":"161","author":"Tebbe","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0530","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11239-011-0549-x","article-title":"Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol","volume":"31","author":"Cohen","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0535","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0540","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1056\/NEJMoa1111288","article-title":"Low-molecular-weight heparin and mortality in acutely ill medical patients","volume":"365","author":"Kakkar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0545","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0550","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1378\/chest.124.3_suppl.11S","article-title":"Thrombin interactions","volume":"124","author":"Di","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0555","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1073\/pnas.96.20.11189","article-title":"Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity","volume":"96","author":"Andersen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0560","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0565","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1124\/mol.107.043182","article-title":"Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes","volume":"73","author":"Pinet","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0570","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.thromres.2008.11.013","article-title":"First report on the effect of thrombin and factor Xa on cardiomyocytes in a three-dimensional cell culture model","volume":"124","author":"Alesci","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0575","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.yjmcc.2005.03.005","article-title":"Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion","volume":"39","author":"Mirabet","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0580","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1161\/CIRCULATIONAHA.111.066787","article-title":"Beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via MMP-13 in cardiac cells","volume":"125","author":"Jaffre","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0585","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000322789","article-title":"Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor","volume":"117","author":"Serebruany","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2010.09.017","article-title":"Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?","volume":"161","author":"Serebruany","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0595","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0600","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0605","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0610","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0615","doi-asserted-by":"crossref","first-page":"38C","DOI":"10.1016\/0002-9149(90)90114-G","article-title":"Antithrombotic therapy in cardiac disease: an approach based on pathogenesis and risk stratification","volume":"65","author":"Fuster","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0620","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"Harper","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0625","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0630","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fca.10.7","article-title":"Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?","volume":"6","author":"Cleland","year":"2010","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0635","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jacc.2004.10.082","article-title":"Aspirin use in chronic heart failure: what should we recommend to the practitioner?","volume":"46","author":"Massie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0640","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cardfail.2007.10.017","article-title":"Venous thromboembolism prophylaxis in hospitalized heart failure patients","volume":"14","author":"Jois-Bilowich","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0645","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/clc.20986","article-title":"Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims","volume":"34","author":"Kociol","year":"2011","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0650","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2012.12.018_bb0655","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0735-1097(98)00006-0","article-title":"Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J Am Coll Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312016476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312016476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T01:33:41Z","timestamp":1562549621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527312016476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0167527312016476"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2012.12.018","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}